Back to News
Market Impact: 0.25
Clearmind Reports U.S. Patent Applications For Drug Combinations In Mental Health
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual Property
Clearmind Medicine announced publication of three U.S. patents covering proprietary drug combinations intended to treat a range of mental health disorders. The patents strengthen the clinical-stage biotechnology company's intellectual-property portfolio, though the announcement does not provide clinical efficacy, regulatory, or commercialization updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CMND0.65
More News
- Trump’s new Medicaid rules will kick in, and GOP states are tougher. Someone may be too frail to work but can’t afford to see a doctor to prove it
- Apple hit with $5.7 billion in damages over haptic patents
- US jury says Apple owes record $5.7 billion in patent case against San Diego company
- Insurers claim AI is already increasing healthcare costs
- ‘Godfather of AI’ explains how humanity could end: Even without a bad actor, AI ‘may derive subgoals that cause it to want to get rid of people’
- White House moves to block $810 million in funding through pocket rescission
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?